

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Medicare Part D - Forteo & Tymlos

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

	Prescriber Name:	
Patient Name:	Supervising Physician:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable)	•
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.		
Q1. For what indication is this drug being prescribed (pick one)?		
☐ Osteoporosis	☐ Other	
Q2. Please provide ICD code(s) for diagnosis.		
Q3. Please select which of the following that apply to the patient.		
☐ Postmenopausal woman		
☐ Man with primary or hypogonadal osteoporosis		
☐ Man or woman with osteoporosis associated with susta	ained systemic glucocorticoid thera	ру
Q4. Is the patient at high risk for fracture defined as having low bone density with a T-score of less than -2.5?		
☐ Yes	□No	
Q5. Is the patient at high risk for fracture defined as history of previous osteoporosis-related fracture?		
☐ Yes	□ No	



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Medicare Part D - Forteo & Tymlos

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

	Prescriber Name:
Patient Name:	Supervising Physician:
Q6. Has the patient experienced failure of oral bisphosphonate therapy?	osphonate therapy defined as new fractures while on oral
☐ Yes	□ No
· ·	erance to oral bisphosphonates. Intolerance includes, but not espepsia, headache, musculoskeletal pain, esophagitis, or other
☐ Yes	□ No
Q8. Additional Comments	
Prescriber Signature	Date
□ Expedited/Urgent - By checking this box and signing seriously jeopardize the life or health of the enrollee or	g above, I certify that applying the standard review timeframe may r the enrollee's ability to regain maximum function
	al necessity denial. Requesting providers may speak to a SWHP pharmacist have an opportunity to help impact the decision on a request before coverage

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document